Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.
Seagen has four treatments on the market. It also has a pipeline of drugs under development that includes potential treatments for a form of lung cancer and advanced breast cancer.
Seagen’s top seller, Adcetris, treats lymph system cancers. It brought in $839 million in sales last year, a 19% increase over the previous year.Seagen also has a deal with Pfizer’s Array BioPharma to develop, make and sell the breast and colorectal cancer treatment Tukysa. It brought in $353 million in sales for Seagen last year.
Bourla said earlier this year that the company planned to use its “extraordinary firepower” to buy products that will deliver $25 billion in incremental revenue by 2030.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Pfizer buys Seagen for $43-billion, boosts access to cancer drugsThe deal will combine Seagen’s technology with Pfizer’s scale and strength, Pfizer CEO Albert Bourla says in a statement
Lire la suite »
Pfizer buys Seagen for $43B, boosts access to cancer drugsPfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.
Lire la suite »
Oil giant Saudi Aramco makes a historic $161-billion profit in 2022Profit credited to rising energy prices Russian invasion of Ukraine, with sanctions limiting the sale of Moscow’s oil and natural gas in Western markets
Lire la suite »
Opinion | ChatGPT is a billion-dollar venture, but can entrepreneurs cash in?The economic value of ChatGPT remains undiscovered, writes economist Graham Dobbs. How entrepreneurs leverage will depend on copyright, licensing and ethical use of AI.
Lire la suite »
Canaccord board members reviewing $1.1-billion management takeover bid resignThe move comes after shareholder Skky Capital publicly called for the special committee to be replaced
Lire la suite »
Trans Mountain expansion's price tag surpasses $30-billion threshold'Buying and building this pipeline will go down in the history books as one of, if not the, worst infrastructure decision a Canadian government has ever made,” said Greenpeace Canada senior energy strategist Keith Stewart.
Lire la suite »